Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03126461
Title SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Texas Southwestern Medical Center
Indications

melanoma

Therapies

Ipilimumab + Nivolumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.